Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CFO Sells 10,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $8.59, for a total transaction of $85,900.00. Following the transaction, the chief financial officer now owns 44,878 shares of the company’s stock, valued at approximately $385,502.02. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Zynex Price Performance

NASDAQ:ZYXI opened at $8.00 on Tuesday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The company has a 50-day moving average of $8.10 and a 200-day moving average of $9.02. Zynex, Inc. has a 52 week low of $7.15 and a 52 week high of $13.77. The company has a market capitalization of $254.77 million, a price-to-earnings ratio of 53.33 and a beta of 0.53.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. During the same quarter last year, the company earned $0.10 earnings per share. The company’s revenue for the quarter was up .1% compared to the same quarter last year. As a group, equities research analysts anticipate that Zynex, Inc. will post 0.2 earnings per share for the current fiscal year.

Institutional Trading of Zynex

A number of large investors have recently bought and sold shares of ZYXI. Vanguard Group Inc. boosted its stake in shares of Zynex by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company’s stock valued at $14,684,000 after purchasing an additional 6,097 shares in the last quarter. Millennium Management LLC boosted its position in Zynex by 66.5% in the second quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after buying an additional 118,615 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Zynex by 1.6% during the second quarter. Bank of New York Mellon Corp now owns 192,832 shares of the company’s stock worth $1,797,000 after buying an additional 2,954 shares during the last quarter. Renaissance Technologies LLC grew its stake in Zynex by 68.7% during the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock worth $1,769,000 after buying an additional 77,300 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its holdings in shares of Zynex by 22.3% during the third quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company’s stock worth $1,179,000 after buying an additional 26,368 shares in the last quarter. 29.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ZYXI shares. Royal Bank of Canada cut their price objective on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. HC Wainwright raised their price objective on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, October 25th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.